Single therapy offers improved survival in younger patients with limited brain metastases
the ONA take:
A study that analyzed patient data from the three largest randomized clinical trials of stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) found that in patients with cancer who are ages 50 years and younger should receive SRS without WBRT.
The meta-analysis examined data from a total of 364 patients from an Asian trial (JROSG99-1), published in 2006; a North American trial (MDACC NCT00548756), published in 2009; and a European trial (EORTC 22952-26001), published in 2011.
The data showed that SRS alone yielded improved overall survival (OS) in patients ages 50 years and younger. Median survival for these patients was 13.6 months after treatment with SRS alone, whereas patients in the same age group who received SRS plus WBRT had a median survival of 8.2 months.
Patients older than 50 years who underwent SRS along had a median survival of 10.1 months, and 8.6 months for those who received SRS plus WBRT.
The researchers reported expecting to see improved survival in patients who received therapy combining SRS and WBRT.
However, these data clearly demonstrated SRS alone offered benefits for younger patients with limited metastases.
Data clearly demonstrated stereotactic radiosurgery alone offered benefits for younger patients with limited metastases.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|